Alectinib Versus Crizotinib in Asian Patients With Treatment-Naïve Advanced ALK-Positive NSCLC: Five-Year Update From the Phase 3 ALESIA Study.
Zhou C, Lu Y, Kim SW, Reungwetwattana T, Zhou J, Zhang Y, He J, Yang JJ, Cheng Y, Lee SH, Chang J, Fang J, Liu Z, Bu L, Qian L, Xu T, Archer V, Hilton M, Zhou M, Zhang L.
Zhou C, et al. Among authors: hilton m.
JTO Clin Res Rep. 2024 Jun 27;5(9):100700. doi: 10.1016/j.jtocrr.2024.100700. eCollection 2024 Sep.
JTO Clin Res Rep. 2024.
PMID: 39282663
Free PMC article.